Extracellular matrix from porcine small intestinal submucosa (SIS) as immune adjuvants

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Aachoui, Youssef ^a   Ghosh, Swapan K ^a  

^a INDIANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CD30 LIGAND; CHEMOTACTIC FACTOR; COLONY STIMULATING FACTOR 1; CRYOPYRIN; IMMUNOGLOBULIN G1; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; KEYHOLE LIMPET HEMOCYANIN; LYMPHOTACTIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; OVALBUMIN; PHTHALIC ACID; PROTEIN LIX; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ALUMINUM SULFATE; CHEMOKINE; CYTOKINE; VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; BIOSAFETY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION REGULATION; IMMUNOGENICITY; MICROARRAY ANALYSIS; MOUSE; NOD LIKE RECEPTOR GENE; NONHUMAN; RECEPTOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMALL INTESTINE MUCOSA; SWINE; TH1 CELL; TH2 CELL; ANIMAL; ANIMAL MODEL; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGY; INFLAMMATION; INTESTINE MUCOSA; SMALL INTESTINE; TRANSPLANTATION;

MUS; SUS;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; CHEMOKINES; CYTOKINES; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; INFLAMMATION; INTESTINAL MUCOSA; INTESTINE, SMALL; MICE; MODELS, ANIMAL; SWINE; TH1 CELLS; TH2 CELLS; VACCINES;

EID: 80455158387     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027083     Document Type: Article

References (45)

1. Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, et al. (2011) Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29: 2461-2473.
2. Mosca F, Tritto E, Muzzi A, Monaci E, Bagnoli F, et al. (2008) Molecular and cellular signatures of human vaccine adjuvants. Proceedings of the National Academy of Sciences 105: 10501-10506.
3. Bornstein P, Sage EH, (2002) Matricellular proteins: extracellular modulators of cell function. Current Opinion in Cell Biology 14: 608-616.
4. Coombe D, (1998) Extracellular matrix volume 1: Tissue function volume 2: Molecular components and interactions. Immunol Cell Biol 76: 114-115.
5. Sottile J, (2004) Regulation of angiogenesis by extracellular matrix. Biochimica et Biophysica Acta (BBA)- Reviews on Cancer 1654: 13-22.
6. Badylak S, Arnoczky S, Plouhar P, Haut R, Mendenhall V, et al. (1999) Naturally occurring extracellular matrix as a scaffold for musculoskeletal repair. Clin Orthop Relat Res pp. S333-343.
7. Badylak S, Kokini K, Tullius B, Simmons-Byrd A, Morff R, (2002) Morphologic Study of Small Intestinal Submucosa as a Body Wall Repair Device. The Journal of surgical research 103: 190-202.
8. Cheng EY, Kropp BP, (2000) Urologic tissue engineering with small-intestinal submucosa: potential clinical applications. World J Urol 18: 26-30.
9. Crapo PM, Wang Y, (2010) Small intestinal submucosa gel as a potential scaffolding material for cardiac tissue engineering. Acta Biomaterialia 6: 2091-2096.
10. Daley WP, Peters SB, Larsen M, (2008) Extracellular matrix dynamics in development and regenerative medicine. J Cell Sci 121: 255-264.
11. Hodde JP, Badylak SF, Brightman AO, Voytik-Harbin SL, (1996) Glycosaminoglycan content of small intestinal submucosa: a bioscaffold for tissue replacement. Tissue Eng 2: 209-217.
12. McPherson TB, Badylak SF, (1998) Characterization of Fibronectin Derived from Porcine Small Intestinal Submucosa. Tissue Engineering 4: 75-83.
13. Voytik-Harbin SL, Brightman AO, Kraine MR, Waisner B, Badylak SF, (1997) Identification of extractable growth factors from small intestinal submucosa. J Cell Biochem 67: 478-491.
14. Bejjani GK, Zabramski J, (2007) Safety and efficacy of the porcine small intestinal submucosa dural substitute: results of a prospective multicenter study and literature review. J Neurosurg 106: 1028-1033.
15. Kropp BP, Eppley BL, Prevel CD, Rippy MK, Harruff RC, et al. (1995) Experimental assessment of small intestinal submucosa as a bladder wall substitute. Urology 46: 396-400.
16. Rosen M, Roselli EE, Faber C, Ratliff NB, Ponsky JL, et al. (2005) Small intestinal submucosa intracardiac patch: an experimental study. Surg Innov 12: 227-231.
17. Allman AJ, McPherson TB, Badylak SF, Merrill LC, Kallakury B, et al. (2001) Xenogeneic extracellular matrix grafts elicit a TH2-restricted immune response. Transplantation 71: 1631-1640.
18. Zhai Y, Ghobrial RM, Busuttil RW, Kupiec-Weglinski JW, (1999) Th1 and Th2 cytokines in organ transplantation: paradigm lost? Crit Rev Immunol 19: 155-172.
19. Suckow MA, Hall P, Wolter W, Sailes V, Hiles MC, (2008) Use of an Extracellular matrix material as a vaccine carrier and adjuvant. Anticancer Research 28: 2529-2534.
20. Ghosh SK, Bankert RB, (1984) Generation of heavy chain-loss mutants in a B cell hybrid mediated by syngeneic idiotype-specific spleen cells. J Immunol 133: 1677-1682.
21. Badylak, (1996) Fluidized intestinal submucosa and its use as an injectable tissue Graft. Patent Number 5516533.
22. Allman AJ, McPherson TB, Merrill LC, Badylak SF, Metzger DW, (2002) The Th2-restricted immune response to xenogeneic small intestinal submucosa does not influence systemic protective immunity to viral and bacterial pathogens. Tissue Eng 8: 53-62.
23. Abramoff MD, Magelhaes PJ, Ram SJ, (2004) Image Processing with ImageJ. Biophotonics International 11: 36-42.
24. Aachoui Y, Chowdhury RR, Fitch RW, Ghosh SK, (2011) Molecular signatures of phytol-derived immunostimulants in the context of chemokine-cytokine microenvironment and enhanced immune response. Cell Immunol.
25. Conti L, Cardone M, Varano B, Puddu P, Belardelli F, et al. (2008) Role of the cytokine environment and cytokine receptor expression on the generation of functionally distinct dendritic cells from human monocytes. Eur J Immunol 38: 750-762.
26. Metcalf D, (1985) The granulocyte-macrophage colony-stimulating factors. Science 229: 16-22.
27. Stanley ER, Berg KL, Einstein DB, Lee PS, Yeung YG, (1994) The biology and action of colony stimulating factor-1. Stem Cells 12 (Suppl 1): 15-24 discussion 25.
28. Janeway CA Jr, (1989) Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 54 Pt 1: 1-13.
29. Matzinger P, (1994) Tolerance, danger, and the extended family. Annu Rev Immunol 12: 991-1045.
30. Ellebedy AH, Lupfer C, Ghoneim HE, DeBeauchamp J, Kanneganti T-D, et al. (2011) Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59. Proceedings of the National Academy of Sciences 108: 2927-2932.
31. Kool M, Pétrilli V, De Smedt T, Rolaz A, Hammad H, et al. (2008) Cutting Edge: Alum Adjuvant Stimulates Inflammatory Dendritic Cells through Activation of the NALP3 Inflammasome. The Journal of Immunology 181: 3755-3759.
32. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J, (2010) Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 11: 136-140.
33. Mathews RJ, Sprakes MB, McDermott MF, (2008) NOD-like receptors and inflammation. Arthritis Res Ther 10: 228.
34. Kuroda Y, Nacionales DC, Akaogi J, Reeves WH, Satoh M, (2004) Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine. Biomedecine & Pharmacotherapy 58: 325-337.
35. Lim SY, Ghosh SK, (2003) Autoreactive responses to an environmental factor: 1. phthalate induces antibodies exhibiting anti-DNA specificity. Immunology 110: 482-492.
36. Lim SY, Meyer M, Kjonaas RA, Ghosh SK, (2006) Phytol-based novel adjuvants in vaccine formulation: 1. assessment of safety and efficacy during stimulation of humoral and cell-mediated immune responses. J Immune Based Ther Vaccines 4: 6.
37. Tschopp J, Schroder K, (2010) NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol 10: 210-215.
38. Petrilli V, Dostert C, Muruve DA, Tschopp J, (2007) The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol 19: 615-622.
39. Kool M, Soullie T, van Nimwegen M, Willart MA, Muskens F, et al. (2008) Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 205: 869-882.
40. Lambrecht BN, Kool M, Willart MAM, Hammad H, (2009) Mechanism of action of clinically approved adjuvants. Current Opinion in Immunology 21: 23-29.
41. Wang HB, Weller PF, (2008) Pivotal advance: eosinophils mediate early alum adjuvant-elicited B cell priming and IgM production. J Leukoc Biol 83: 817-821.
42. Kennedy MK, Willis CR, Armitage RJ, (2006) Deciphering CD30 ligand biology and its role in humoral immunity. Immunology 118: 143-152.
43. Reiter R, Pfeffer K, (2002) Impaired germinal centre formation and humoral immune response in the absence of CD28 and interleukin-4. Immunology 106: 222-228.
44. Suckow M, Rosen E, Wolter W, Sailes V, Jeffrey R, et al. (2007) Prevention of human PC-346C prostate cancer growth in mice by a xenogeneic tissue vaccine. Cancer Immunology, Immunotherapy 56: 1275-1283.
45. Billiau A, Matthys P, (2001) Modes of action of Freund's adjuvants in experimental models of autoimmune diseases. J Leukoc Biol 70: 849-860.